|
US4447A
(en)
|
|
1846-04-04 |
|
Car- wheel |
|
US233A
(en)
|
|
1837-06-14 |
|
Improvement in plows |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
US4615885A
(en)
|
1983-11-01 |
1986-10-07 |
Terumo Kabushiki Kaisha |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
US4965195A
(en)
|
1987-10-26 |
1990-10-23 |
Immunex Corp. |
Interleukin-7
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
WO1991018982A1
(en)
|
1990-06-05 |
1991-12-12 |
Immunex Corporation |
Type ii interleukin-1 receptors
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US6239328B1
(en)
|
1992-10-05 |
2001-05-29 |
North Carolina State University |
Method for reducing expression variability of transgenes in plant cells
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US6037525A
(en)
|
1996-08-01 |
2000-03-14 |
North Carolina State University |
Method for reducing expression variability of transgenes in plant cells
|
|
US6245974B1
(en)
|
1997-08-06 |
2001-06-12 |
North Carolina State University |
Matrix attachment regions
|
|
CN1204147C
(zh)
|
1998-02-25 |
2005-06-01 |
利思进药品公司 |
提高以抗体为基础的融合蛋白的循环半衰期的方法
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6177612B1
(en)
|
1998-07-31 |
2001-01-23 |
Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada |
Matrix attachment regions
|
|
US6388066B1
(en)
|
1998-09-29 |
2002-05-14 |
Pioneer Hi-Bred International, Inc. |
MAR/SAR elements flanking RSYN7-driven construct
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
KR100408844B1
(ko)
|
2000-07-29 |
2003-12-06 |
한국산업기술평가원 |
동물세포 발현벡터
|
|
WO2002048379A1
(en)
|
2000-12-15 |
2002-06-20 |
Pangen Biotech Inc. |
Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
|
|
EP1395669B1
(en)
|
2001-01-26 |
2009-07-22 |
Selexis S.A. |
Matrix attachment regions and methods for use thereof
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
NZ536746A
(en)
|
2002-06-13 |
2007-02-23 |
Crucell Holland Bv |
An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
|
|
ATE514783T1
(de)
|
2003-11-12 |
2011-07-15 |
Schering Corp |
Plasmidsystem zur expression mehrerer gene
|
|
EP1723251A4
(en)
|
2004-03-05 |
2008-04-23 |
Novartis Vaccines & Diagnostic |
IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
|
|
CN101146823A
(zh)
|
2005-02-15 |
2008-03-19 |
阿波罗生命科学有限公司 |
分子及其嵌合分子
|
|
MX2007009908A
(es)
|
2005-02-15 |
2007-10-03 |
Novartis Vaccines & Diagnostic |
Metodos para tratar linfomas utilizando una combinacion de un agente quimioterapeutico e il-2 y opcionalmente un anticuerpo anti-cd20.
|
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
US7695963B2
(en)
|
2007-09-24 |
2010-04-13 |
Cythera, Inc. |
Methods for increasing definitive endoderm production
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US20110274650A1
(en)
|
2009-01-21 |
2011-11-10 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
BRPI1008692B8
(pt)
|
2009-02-17 |
2021-05-25 |
Ucb Biopharma Sprl |
anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
|
|
WO2011106707A2
(en)
|
2010-02-26 |
2011-09-01 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to dr3
|
|
WO2012027328A2
(en)
*
|
2010-08-23 |
2012-03-01 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
HRP20180858T1
(hr)
|
2011-07-11 |
2018-09-21 |
Glenmark Pharmaceuticals S.A. |
Protutijela koja se vežu na ox40 i njihove uporabe
|
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ｏｘ４０ 항체 및 이의 사용 방법
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
MA40682B1
(fr)
|
2014-03-31 |
2020-01-31 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation correspondants
|
|
JP2017511381A
(ja)
|
2014-04-04 |
2017-04-20 |
協和発酵キリン株式会社 |
アゴニスト活性が低減された抗デスレセプター３（ｄｒ３）アンタゴニスト抗体
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
EP3148573A4
(en)
*
|
2014-05-29 |
2017-11-15 |
Medimmune, LLC |
Ox40l fusion proteins and uses thereof
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
WO2017136818A2
(en)
|
2016-02-05 |
2017-08-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
CN115073581A
(zh)
|
2016-05-04 |
2022-09-20 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
BR112019012328A2
(pt)
|
2016-12-15 |
2019-11-19 |
Abbvie Biotherapeutics Inc |
anticorpos anti-ox40 e seus usos
|
|
US11407806B2
(en)
*
|
2017-04-06 |
2022-08-09 |
Albert Einstein College Of Medicine |
Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
|
|
JP2019122373A
(ja)
*
|
2018-01-12 |
2019-07-25 |
アムジエン・インコーポレーテツド |
抗ｐｄ−１抗体及び治療方法
|
|
CN112105632A
(zh)
*
|
2018-01-24 |
2020-12-18 |
北京智康博药肿瘤医学研究有限公司 |
细胞因子融合蛋白
|
|
CN108285490A
(zh)
*
|
2018-01-26 |
2018-07-17 |
西南交通大学 |
一种高亲和性结合i型胶原蛋白的gst融合蛋白制备及其应用
|
|
KR20220035122A
(ko)
*
|
2019-06-14 |
2022-03-21 |
큐진 인크. |
신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자
|